Skip to main content
main-content

03-03-2017 | Image

Figure 2: Key milestones in the development of the artificial pancreas

Figure 2: Key milestones in the development of the artificial pancreas

Blood glucose monitors were first introduced into clinical practice in the late 1960s, and the clinical feasibility of insulin pumps was established in the 1970s. Minimally invasive continuous glucose monitoring (CGM) progressed to factory-calibrated systems for insulin dosing, and CGM first became commercially available in 2000. These advances have been combined into the artificial pancreas system [3,4]. The FDA approved the MiniMed 670G hybrid closed-loop system for use in patients with type 1 diabetes aged 14 years and over in September 2016. CGM, continuous glucose monitoring. FDA, Food & Drug Administration.

OPTIMIZ MEDICAL/b4producer/Miriam Dörr/Abbott Diabetes Care/Judy Barranco/Ralph Maats/Medtronic